Abstract
Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aimed to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We conducted a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality was extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses included patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine was 1.11 (95% CI: 1.02, 1.20; I2=0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I2=0%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine was associated with increased mortality in COVID-19 patients, and there was no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.
Competing Interest Statement
Benjamin Abella and Ravi Amaravadi are the primary investigators of the Prevention and Treatment of COVID19 with Hydroxychloroquine (PATCH) trial, funded by a philanthropic gift. Ravi Amaravadi reports being founder with equity of Pinpoint Therapeutics and Immunacell, and personal fees from Sprint Biosciences and Deciphera, outside the submitted work. Derek Angus reports personal fees from Ferring Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bayer AG, other from Alung Technologies, Inc., outside the submitted work; in addition, Dr. Angus has pending patents for Selepressin compounds, compositions and methods for treating sepsis to Ferring, B.V., and Proteomic biomarkers of sepsis in elderly patients pending to University of Pittsburgh. Yaseen Arabi reports that he is principal investigator on a clinical trial of lopinavir-ritonavir and interferon for Middle East respiratory syndrome (MERS) and that he was a non-paid consultant on therapeutics for MERS-coronavirus (CoV) for Gilead Sciences and SAB Biotherapeutics. He is a co-investigator on the Randomized, Embedded, Multi-factorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP), a board member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), and the Lead-Co Chair of the Think20 (T20) Taskforce for COVID-19. Brigham and Women's Hospital, PRA Health Science, and Cliniques universitaires Saint-Luc received funds from Sanofi. Thomas Benfield reports grants from Pfizer, Novo Nordisk Foundation, Simonsen Foundation, Lundbeck Foundation, and Kai Hansen Foundation; grants and personal fees from GSK, Pfizer, Boehringer Ingelheim, and Gilead; and personal fees from MSD, all outside the submitted work. Yehuda Cohen, Lisa Cowan, Bruno Igau, and Laurent Perrin are employees of Sanofi. The COV-HCQ and COMIHY trials were supported by the German Federal Ministry of Education and Research (EudraCT number 2020-001224-33) and the German Federal Ministry of Health (EudraCT number 2020-001512-26). Lennie Derde reports grants from EU FP7-HEALTH-2013-INNOVATION-1, grant number 602525, grants from H2020 RECOVER grant agreement No 101003589, during the conduct of the study; and is a member of the COVID-19 guideline committee SCCM/ESICM/SSC, member of the ESICM COVID-19 taskforce, and chair of the Dutch intensivists (NVIC) taskforce infectious threats. Vincent Dubee reports non-financial support from MSD France and from Sanofi Aventis France, outside the submitted work. Anissa Elfakir is an employee of Ividata Life Sciences and works as an external contractor for Sanofi. Anthony Gordon received grant funding from a NIHR Research Professorship (RP-2015-06-18), support from the NIHR Imperial Biomedical Research Centre, and consulting fees paid to his institution from GlaxoSmithKline and Bristol Myers Squibb. Thomas Hills reports grants from the Health Research Council of New Zealand, during the conduct of the study. Andy Hoepelman reports grants from ZonMw, Netherlands organisation for Health Research and Development, during the conduct of the study. HYDRA trial was an investigator-initiated study supported by Sanofi, CONACYT (National Council of Science and Technology of Mexico) and by the participating centers. Thuy Le reports grants from Gilead Sciences, outside the submitted work. Bryan McVerry reports grants from NIH/NHLBI, and from Bayer Pharmaceuticals, Inc., outside the submitted work. Srinivas Murthy receives funding as the Innovative Medicines Canada Chair in Pandemic Preparedness. Colin McArthur reports grants from the Health Research Council of New Zealand. Mark Mulligan reports having received the HCQ drug from the New York State government, during the conduct of the study; grants from Lilly, Pfizer, Sanofi, and personal fees from Meissa, outside the submitted work; in addition, Dr. Mulligan has a patent anti-Zika monoclonal ab/ Emory Univ pending. Alistair Nichol is supported by a Health Research Board of Ireland Clinical Trial Network Award (HRB-CTH-2014-012). Lena Perez is an employee of Excelya and works as an external contractor for Sanofi. Frank Rockhold reports personal fees from Merck Research Labs, Novartis, Lilly, Sanofi, NovoNordisk, KLSMC, Tolerion, Rhythm, UCB, AstraZeneca, Janssen, Merck KGaA, Sarepta, Eidos, Amgen, Phathom, outside the submitted work; and having equity interest in GlaxoSmithkline, Athira Pharma, DataVant, Spencer Healthcare. Stephen Walsh reports receiving a grant from Sanofi during the conduct of the study and grants from NIH-NIAID outside the submitted work, and having conducted vaccine (HIV, Zika) clinical trials funded by Janssen. Steve Webb reports grants from National Health and Medical Research Council (Australia), grants from Minderoo Foundation, from Health Research Council (New Zealand), and from Medical Research Future Fund (Australia), during the conduct of the study. Jesper Weehuizen reports grants from ZonMw, Netherlands organisation for Health Research and Development, during the conduct of the study. Fernando Zampieri was part of the Coalition 1 trial partially supported by EMS Pharmaceuticals, has received previous grants from Bactiguard, Sweden, outside the submitted work and support from Baxter LA for another clinical trial in critically ill patients. None of the other authors have any competing interests to declare.
Clinical Protocols
Funding Statement
This collaborative meta-analysis was supported by the Swiss National Science Foundation and Laura and John Arnold Foundation (grant supporting the post-doctoral fellowship at the Meta-Research Innovation Center at Stanford (METRICS), Stanford University). Funding also includes postdoctoral grants from Uppsala University, the Swedish Society of Medicine, the Blanceflor Foundation and the Sweden-America Foundation (C. Axfors). The funders had no role in the design of this collaborative meta-analysis; in the collection, analysis, and interpretation of data; or in the report writing. The corresponding author had full access to all study data and final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a meta-analysis (why we are not listing details on ethics approval of included studies).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article and its supplementary information files.
